Overview
SRPT market data
Price History
SRPT price chart · 1M
- O
- 19.21
- H
- 22.58
- L
- 18.77
- C
- 22.14
- Vol
- 417,473.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $19.21
- Previous Close
- $19.47
- Day High
- $22.58
- Day Low
- $18.77
- 52 Week High
- $23.48
- 52 Week Low
- $14.70
- 7 Day Return
- +15.13%
- 30 Day Return
- +43.30%
- 90 Day Return
- +23.76%
- 1 Year Return
- +7.03%
- Daily Notional Volume
- $9.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.13 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.34 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -6.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.68 – $25.32 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.9B · P/B 1.98 · P/S 0.98.
Company News
Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M EstimateBenzinga · Aug 5, 2026, 8:14 PM
8-K filing — Sarepta Therapeutics, Inc. (SRPT)SEC EDGAR · Jul 27, 2026, 1:08 PM
Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug IngramBenzinga · Jul 27, 2026, 12:37 PM
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20Benzinga · Jul 9, 2026, 3:40 PM
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price TargetBenzinga · Jul 9, 2026, 12:15 PM
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy DrugsBenzinga · Jun 30, 2026, 4:50 PM
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027Benzinga · Jun 30, 2026, 12:40 PM
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market TodayBenzinga · Jun 17, 2026, 5:40 PM